Clinical Trial Update: Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour [Phase 1]

View source ↗

Summary

Phase I study evaluating cediranib in combination with lomustine for recurrent malignant brain tumors has completed (sponsored by AstraZeneca).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Glioblastoma

Drugs mentioned

• Cediranib (Cediranib)
• Lomustine (Lomustine)

Snippet

Sponsor: AstraZeneca | Conditions: Recurrent Glioblastoma, Brain Tumor | Phase 1 | Status: COMPLETED